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Prophylactic pharmacological activation of astrocytic gene expression driven by the transcription factor Nrf2 boosts antioxidant
defences and protects against neuronal loss in ischemia and other disease models. However, the role of Nrf2 in mediating
endogenous neuroprotective responses is less clear. We recently showed that Nrf2 is activated by mild oxidative stress in both
rodent and human astrocytes. Moreover, brief exposure to ischemic conditions was found to activate Nrf2 both in vivo and in vitro,
and this was found to contribute to neuroprotective ischemic preconditioning. Here we show that transient ischemic conditions in
vitro and in vivo cause an increase in the expression of Nrf2 target genes associated with the glutathione pathway, including those
involved in glutathione biosynthesis and cystine uptake. Taken together, these studies indicate that astrocytic Nrf2 may represent
an important mediator of endogenous neuroprotective preconditioning pathways.
1. Introduction
1.1. Nrf2 Is aMaster Regulator of Antioxidant Gene Expression.
Many acute and chronic neurological disorders are associat-
ed with oxidative stress, caused by an imbalance in the pro-
duction and detoxification of reactive oxygen species (ROS).
Nuclear factor-erythroid 2-related factor 2 (Nrf2), a member
of the cap“n”collar transcription factor family, is a master
regulator of antioxidant defense genes and drug-metaboliz-
ing enzymes [1, 2]. The binding of Nrf2 to a cisacting DNA
promoter sequence, called the antioxidant response element
(ARE), allows transactivation of a group of cytoprotective
genes [1, 2]. Under normal conditions Nrf2 is bound to
Kelch-like ECH-associated protein 1 (Keap1), and through a
two-site interaction, the transcription factor is ubiquitinated
by Cul3/Rbx1 and targeted for degradation [3]. However,
under oxidative stress conditions the two-site interaction
between Nrf2 and Keap1 is disrupted, allowing Nrf2 to
evade Keap1-mediated ubiquitination and accumulate in the
nucleus where it activates genes with an ARE sequence within
their promoters, leading to an induction of antioxidant
machinery [2]. Upregulation of the ARE-gene battery has
a significant impact on the ability of the cell to withstand
and survive sustained oxidative insults. Prophylactic Nrf2
activation by small molecules is protective against a host of
oxidative insults in vitro, including free radical donors and
oxygen glucose deprivation (OGD), as well as toxic levels of
glutamate or N-methyl-D-aspartate (NMDA, [4–6]). Nrf2
activation in vivo is similarly protective, reducing neurotoxin
or stroke-induced injury [5, 7, 8].
1.2. Nrf2-Mediated Neuroprotection in the CNS. Nrf2 has
an integral role in mediating antioxidant responses within
the CNS. Nrf2-dependent gene expression in astrocytes can
protect neurons against a variety of trauma and disease-
causing agents [9–14]. In these studies, however, Nrf2-
dependent gene expression was achieved artificially, either
via astrocyte-specific overexpression of Nrf2, or through
treatment with well-characterized small molecule activators
of the pathway. The latter is in essence a form of chem-
oprevention, whereby prophylactic administration of small
molecule Nrf2 activators confers significant neuroprotection
[4, 5, 7, 15]. Indeed, fibroblasts are also rendered resistant to
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many electrophiles, peroxides, and redox-cycling agents, in
an Nrf2-dependent fashion, by pretreatment or “priming,”
with nontoxic doses of chemopreventive agents such as
sulforaphane [16]. Prophylactic administration of Nrf2 ac-
tivators can be considered an artificial pharmacological form
of preconditioning, whereby exogenous activation of the
antioxidant response renders the cell better able to defend
itself from a subsequent insult. However, little was known as
to what endogenous signals might trigger an Nrf2-depend-
ent, physiologically relevant, endogenous, neuroprotective
response.
2. Results and Discussion
2.1. Ischemia and Oxidative Stress Activate Nrf2 in Astrocytes.
In nonneural cells, oxidative stress is known to activate Nrf2
through inhibition of Keap1-dependent Nrf2 degradation.
This is eﬀected at least in part via the modification of key
cysteine residues in Keap1 and may result in the formation
of disulfide bonds [17] and possibly conformational changes
in the adaptor protein [2]. To investigate whether oxidative
stress activates Nrf2 in neural cells, we chose two experi-
mental models which recreate this in vitro, OGD and H2O2
application [18]. Exposure times or concentrations were
selected, which bridged both lethal and sublethal doses in
order to confirm oxidative-stress-dependent Nrf2 activation
in physiologically relevant, viable conditions. Peroxide is a
ROS with clearly identified roles in contributing to oxidative
stress, while OGD and subsequent reoxygenation trigger a
complex cascade of detrimental events including excitoxicity,
cytosolic and mitochondrial ROS generation, and inflam-
matory responses (for review see [19]). Anoxia causes an
accumulation of reducing equivalents within the electron
transport chain, which upon reperfusion triggers a burst of
ROS production [20]. Oxidative stress and ROS production
also arise from impaired glutamate signaling due to excessive
transmitter release and a reversal of glutamate uptake
transporters. As a result excessive NMDAR activity triggers
superoxide production via NADPH oxidase activation and
xanthine oxidase [21].
We found that both OGD and mild oxidative stress
(subtoxic H2O2) applied to mixed neuronal/astrocytic cul-
tures [18] induced expression of Nrf2 target genes [18],
including the classical target gene, hemeoxygenase (Hmox1)
and the more recently identified target gene, sulfiredoxin
(Srxn1). Given that the Srxn1 and Hmox1 genes can respond
to factors other than Nrf2 [22], whether Nrf2 was the
specific transcription factor mediating the gene induction
following ischemia or H2O2 application remained unclear.
To determine this, the same protocols were employed on
Nrf2 −/− cultures revealing no significant gene induction
after OGD or after H2O2 application in the absence of
Nrf2, highlighting the central role of endogenous Nrf2 in
mediating this gene induction [18]. Of note, we found that
the locus of Nrf2 activation within the mixed cultures is
centred on the astrocytes. Induction of Nrf2 target genes
by OGD or oxidative stress was not observed in pure
neuronal cultures devoid of astrocytes, while activation in
pure astrocytic cultures was found to be highly robust [18].
Immunofluorescent analysis in mixed cultures of Hmox1
induction by oxidative stress also revealed induction that was
specific to GFAP-positive astrocytes [18].
2.2. Astrocytic Nrf2 Contributes to Neuroprotective Ischemic
Preconditioning. We next assessed whether the aincrease in
Nrf2-regulated gene expression translated into enhanced
protection, by quantifying neuronal viability following OGD
in Nrf2 −/− and wild-type mixed cultures. Following OGD
no diﬀerence in survival was observed between the Nrf2
wild-type and−/− neurons [18], which was perhaps surpris-
ing given the known protective capacity of Nrf2, although
easily explained by the fact that Nrf2 target gene induction by
this toxic insult was arising too late to confer protection. We
next hypothesized that a sublethal insult might be suﬃcient
to activate Nrf2, potentially contributing to neuroprotective
ischemic preconditioning [23]. We established a precondi-
tioning protocol, where a nontoxic 1.5 h exposure to OGD
conferred significantz neuroprotection against a toxic 3 h
OGD insult applied 24 h later [18]. To determine whether the
initial 1.5 h OGD insult led to recruitment of the Nrf2 path-
way, Nrf2-dependent gene expression was assessed following
the preconditioning stimulus. The 1.5 h OGD precondition-
ing stimulus led to a significant upregulation in both Srxn1
and Hmox1 gene expression, demonstrating activation of the
Nrf2 pathway [18]. This suggested a possible contribution of
astrocytic Nrf2 activation in the neuroprotection incurred by
our preconditioning protocol.
To determine the role of Nrf2 in the protective eﬀect of
ischemic preconditioning, Nrf2 wild-type and −/− mixed
cultures were exposed to the preconditioning protocol.While
a preconditioning-induced increase in viability was apparent
in both Nrf2 wild-type and −/− neurons, the magnitude
of the protective eﬀect of preconditioning was significantly
diminished in the absence of Nrf2 [18]. Preconditioning
reduced the total amount of OGD-induced death by around
60% in wild-type neurons, but by under 30% in Nrf2-
deficient neurons [18]. Thus, Nrf2 activation is responsible
for a significant portion of the protective eﬀect of ischemic
preconditioning in vitro. We next determined whether the
Nrf2 pathway might also be implicated in in vivo precon-
ditioning. To achieve this, Nrf2 target gene expression was
assessed in mice subjected to a 15-minute occlusion of the
middle cerebral artery (MCA), a stimulus known to trigger
preconditioning and confer significant protection from sub-
sequent ischemic episodes in vivo [24]. Cortical extracts from
the ipsilateral hemisphere revealed a significant upregulation
of both Srxn1 and Hmox1 following transient occlusion [18],
demonstrating that an ischemic preconditioning episode in
vivo activates the Nrf2 pathway.
2.3. Activation of Nrf2-Regulated Glutathione Pathway Genes
by Preconditioning Stimuli. In addition to Srxn1 and Hmox1,
Nrf2 also regulates the expression of enzymes involved in glu-
tathione synthesis and utilisation, a systemwhich contributes
substantially to cells’ antioxidant capacity. Indeed, activation
of Nrf2 in astrocytes by overexpression of small molecules is
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Figure 1: In vitro preconditioning activates Gclc expression. neurons were exposed to the 1.5 h OGD preconditioning stimulus and
the expression of Nrf2-target genes. Gclc and xCT were determined by qPCR. Expression of both xCT and Gclc was significantly
upregulated by the preconditioning stimulus, highlighting a potential contribution of their gene products in the neuroprotection acquired
by preconditioning (bars represent mean ± SEM, ∗P < .05, unpaired t-test, n = 3 for Gclc, n = 5 for xCT).
thought to promote neuroprotection due to the coordinated
upregulation of glutathione synthesis and release, leading to
increased availability of glutathione precursors for nearby
neurons to use to enhance their own glutathione pool
[25].
To determine whether glutathione pathway genes are
induced following preconditioning, gene expression of rep-
resentative Nrf2-controlled glutathione pathway members
were quantified by quantitative real-time PCR (qPCR) 4 or
8 h following exposure to the 1.5-hour OGD precondition-
ing stimulus. Expression of glutamate-cysteine ligase (Gclc)
and glutamate/cystine antiporter (xCT) was assessed; Gclc
encodes the catalytic subunit of the rate-limiting enzyme of
glutathione synthesis, and xCT encodes a cystine/glutamate
transporter and represents the major mechanism for obtain-
ing cysteine for glutathione synthesis. Exposure to the
ischemic preconditioning stimuli conferred a significant
increase in Gclc gene expression (Figure 1(a), ∗P < .05,
unpaired t-test, n = 3) and a near significant increase in
xCT expression 4 h following OGD (Figure 1(b), P = .06,
unpaired t-test, n = 5). To assess whether recruitment
of the glutathione pathway might also occur in vivo, adult
mice were subjected to a 15-minute occlusion of the MCA,
which as mentioned above is a stimulus known to trigger in
vivo preconditioning. Four hours later, mice were sacrificed
and cortical tissue was harvested from the ipsilateral and
contralateral hemispheres for RNA isolation and qPCR.
Transient occlusion of the MCA triggered a significant
upregulation in the mRNA expression of both Gclc and xCT
in the ipsilateral cortex (see Figures 2(a) and 2(b), ∗∗P < .01,
∗∗∗P < .001, Student’s t-test, n = 6), as well as in the
expression of another Nrf2 target gene, Glutamate-cysteine
ligase regulatory subunit (Gclm) (Figure 2(c), ∗∗∗P < .001,
Student’s t-test, n = 6), suggesting a potential contribution
of these gene products to the resultant neuroprotection
acquired by ischemic preconditioning in vivo. Thus, a variety
of Nrf2 target genes are induced by transient ischemia
in vivo.
2.4. Nrf2-Dependent and Nrf2-Independent Mechanisms of
Astrocyte-Mediated Neuroprotection. Our finding that astro-
cytic Nrf2 plays a role in preconditioning is in line with
studies identifying ROS production as a necessary event in
the establishment of preconditioning [26] and the finding
that superoxide radicals or H2O2 is capable of activating
the preconditioning response [27]. Moreover, our finding
that the gene expression of key markers of the glutathione
pathway is increased following in vitro and in vivo precondi-
tioning supports a neuroprotective role for the glutathione
pathway in the Nrf2-dependent component of ischemic
preconditioning. Indeed, numerous studies have identified
glutathione as being involved in preconditioning [28, 29],
and chemopreventive protection is associated with a marked
upregulation of glutathione biosynthesis [16], as is Nrf2
activation in the brain [7, 15].
In contrast to our own findings, a recent study identi-
fied an Nrf2-independent neuroprotective eﬀect following
subtoxic H2O2 generation in astrocytes [30]. The authors
utilized an elegant system whereby the expression of a
H2O2-producing enzyme in astrocytes led to a specific and
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Figure 2: Upregulation of glutathione pathway components following in vivo ischemic preconditioning. Gene expression of glutathione
pathway components, Gclc (a), xCT (b), and Gclm (c), was quantified by qPCR in mice subjected to a transient 15-minute occlusion of the
middle cerebral artery, a stimulus known to trigger neuroprotective preconditioning in vivo. Transient ischemia significantly increased the
cortical expression of Gclc, xCT, and Gclm in the ipsilateral hemisphere, as compared to the contralateral hemisphere, suggesting a specific
recruitment of the ARE/Nrf2/glutathione pathway in the protective eﬀects of preconditioning in vivo (bars represent mean± SEM,∗∗P < .01,
∗∗∗P < .001, Student’s t-test, n = 6).
quantifiable level of H2O2 production following application
of D-alanine. This in turn led to a protective response
in astrocytes that rendered neurons resistant to an oxida-
tive insult. However, this response was not dependent on
astrocytic Nrf2 activation and potentially involved tyrosine
phosphatase inhibition [30]. While the potential reasons
behind the disparities between the two studies are discussed
elsewhere [18], it is feasible that both Nrf2-dependent and
Nrf2-independent mechanisms can contribute to adaptive
neuroprotective responses by astrocytes to mild oxidative
insults. Moreover, the importance of individual pathways
may depend on developmental stage or the severity or nature
of the oxidative insult. Notwithstanding these issues, it is
clear that astrocytes are important mediators of adaptive
neuroprotective responses to subtoxic insults.
2.5. Concluding Remarks. Our identification of astrocytic
Nrf2, a mediator of endogenous ischemic preconditioning,
underlines the importance of astrocytes in shaping neuronal
vulnerability to insults. Moreover it emphasizes the potential
value of astrocytic Nrf2 as a therapeutic target in a variety
of disorders associated with oxidative stress [31]. Since Nrf2
controls multiple components of both the glutathione system
and the thioredoxin-peroxiredoxin system [2, 31, 32], it has
the capacity to mount a coordinated antioxidant response
to oxidative insults in the brain. While studies have been
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focussed on rodent systems, it will be important to determine
whether human astrocytes are capable of mediating a neu-
roprotective response to Nrf2-activating stimuli, something
that human stem-cell-based approaches are now capable of
answering.
3. Materials and Methods
3.1. Neuronal Cultures. Cortical mouse mixed cultures of
neurons and astrocytes were prepared as described [33] from
E17.5 CD1 mice with neurobasal growth medium supple-
mented with B27 (Invitrogen, Carlsbad, Calif, USA). These
cultures involve approximately 90% NeuN-positive neurons
and 10% GFAP-positive astrocytes [34]. Experiments were
carried out on cultured neurons following a period of 8–
10 days during which cortical neurons develop a network of
processes, express functional NMDA-type and AMPA/kain-
ate-type glutamate receptors, and form synaptic contacts.
Prior to the start of experiments, neurons were subjected to
trophic deprivation by transferring them from growth medi-
um to TMo for two hours, a medium containing 10% MEM
(Invitrogen) and 90% salt-glucose-glycine (SGG) medium
(SGG: 114mM NaCl, 0.219% NaHCO3, 5.292mM KCl,
1mM MgCl2, 2mM CaCl2, 10mM HEPES, 1mM glycine,
30mM glucose, 0.5mM sodium pyruvate, 0.1% phenol red;
osmolarity 325mosm/l, [35]).
3.2. Oxygen Glucose Deprivation. OGD was performed on
DIV = 9 cultured mouse neurons. Cells were transferred
from TMo, washed once in a glucose-free, balanced salt
solution (SGG with mannitol substituted for glucose, SGG-
Mann): 114mM NaCl, 0.219% NaHCO3, 5.292mM KCl,
1mM MgCl2, 2mM CaCl2, 10mM HEPES, 1mM glycine,
30mM mannitol, 0.5mM sodium pyruvate, 0.1% phenol
red; osmolarity 325mosm/l solution, which had previously
been degassed by flushing the solution with 95% N2-5% Co2
for 30min. Cells were placed in degassed glucose-free SGG-
Mann and put in a modular incubator chamber, which was
flushed with 95% N2-5% Co2 for 4min at a flow rate of
20 L/min, according to manufacturer’s instructions (Billups-
Rothenburgh, Del Mar, Calif, USA), in order to fully expel
any remaining oxygen within the chamber. The chambered
cells were then left in OGD at 37◦C for 3 h, before being
returned to normoxic conditions and glucose-containing
media (TMo). No OGD control cells were placed in SGG
and maintained in normoxic conditions for 3 h before also
being returned to TMo. All cells were left in TMo until RNA
isolation for the time point indicated. Anaerobic conditions
within the modular incubator chamber were confirmed with
Dry Anaerobic Indicator Strips (Fisher Scientific, Loughbor-
ough, UK).
3.3. RNA Isolation, RT-PCR, and qPCR. RNA was isolated
using the Stratagene Absolutely RNA Miniprep kit as
directed by the manufacturer, including the optional DNAse
treatment (Stratagene, Amsterdam, Netherlands). For qPCR,
cDNA was synthesized from 1–3 µg RNA using the Stratas-
cript QPCR cDNA Synthesis kit (Stratagene) according to
the manufacturer’s instructions and as described previously
[6, 34]. Briefly, the required amount of RNA (up to 3 µg) was
diluted in RNase-free water (up to 7 µL final volume) and
mixed on ice with 2x cDNA Synthesis master mix (10 µL),
random primers: oligo-dT primers 3:1 (total 2 µL–200 ng),
and either 1 µL RT/RNase block enzyme mixture (for RT
reactions) or 1 µL water (for no-RT control reactions). Reac-
tion mixtures were mixed, spun down, and incubated for
2min at 25◦C, 40 min at 42◦C, and 5min at 95◦C. cDNA was
stored at −20◦C. Dilutions of this cDNA were subsequently
used for real-time PCR (cDNA equivalent to 6 ng of initial
RNA per 15 µL qPCR reaction for all genes). qPCR was per-
formed in an Mx3000P qPCR System (Stratagene) using
Brilliant SYBR Green qPCR Master Mix (Stratagene) accord-
ing to the manufacturer’s instructions. Briefly, the required
amount of template was mixed on ice with 2x Brilliant SYBR
Green Master Mix, forward and reverse primers at 200 nM
each final concentration, 30 nM final concentration ROX
passive reference dye, and water to the required reaction
volume. Technical replicates as well as no-template and no-
RT negative controls were included, and at least 3 biological
replicates were studied in each case. The sequence of the
utilized primers is as follows (all at 200 nM final): xCT-F: 5′-
ATACTCCAGAACACGGGCAG-3′, xCT-R: 5′-AGTTCC-
ACCCAGACTCGAAC-3′, Gclc-F: 5′-CCAACCATCCGA-
CCCTCTG-3′, Gclc-R: 5′-TGTTCTGGCAGTGTGAAT-
CC-3′, Gclm-F: 5′-GCACAGCGAGGAGCTTC-3′, Gclm-R:
5′-GAGCATGCCATGTCAACTG-3′, GAPDH-F: 5′-GGG-
TGTGAACCACGAGAAAT-3′, GAPDH-R: 5′-CCTTCC-
ACAATGCCAAAGTT-3′. The qPCR cycling programme
was 10min at 95◦C; 40 cycles of 30 sec at 95◦C, 40 sec at 60◦C
with detection of fluorescence, and 30 sec at 72◦C; 1 cycle (for
dissociation curve) of 1min at 95◦C and 30 sec at 55◦C with
a ramp up to 30 sec at 95◦C (ramp rate: 0.2◦C/sec) with con-
tinuous detection of fluorescence on the 55–95◦C ramp.
Data were analysed using the MxPro qPCR analysis software
(Stratagene), and the expression of the gene of interest was
normalized to GAPDH, a commonly used control.
3.4. In Vivo Focal Cerebral Ischemia. All experiments were
carried out in adult male C57Bl/6J mice (Charles River, UK)
under an appropriate Home Oﬃce Licence and adhered to
regulations as specified in the Animals (Scientific Proce-
dures) Act (1986). Transient focal ischemia (15min) was
induced by intraluminal filament occlusion of the right
middle cerebral artery (MCA). Animals were anaesthetized
and maintained with isoflurane (2%) in a mixture of 30%
O2 and 70% N2O by face mask. Focal cerebral ischemia was
induced by the occlusion of the rightMCAwith an 8–0 nylon
monofilament (Ethicon, Kirkton, Scotland) coated with a
mixture of silicone resin (Xantoprene, Bayer Dental, Osaka,
Japan) and hardener (Elastomer Activator, Bayer Dental).
Briefly, the right common carotid (CCA), external carotid
(ECA), and internal carotid (ICA) arteries and their branches
were exposed through a midline cervical incision. A 6–0 silk
suture was tied around the CCA proximal to the bifurcation
of the ECA and ICA and then a second suture tied around
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the ECA distal to the superior thyroid artery (STA). The STA
and occipital artery (OA) were closed by electrocoagulation.
The silicone-coated monofilament (diameter 220 µm) was
introduced into the CCA via a small incision and advanced
10mm distal to the carotid bifurcation so as to occlude
the MCA. Following the occlusion, mice were then recov-
ered from anaesthesia briefly and placed in an incubator
(30◦C) before being reanesthetized in order to remove the
monofilament to allow reperfusion. Wounds were sutured
closed and anaesthesia discontinued. After reperfusion of
3.75 h (n = 6), mice were reanesthetized briefly with 5%
isoflurane and decapitated. The brains were rapidly removed,
and the regions supplied by the MCA (striatum and cortex)
were dissected within the ipsilateral and contralateral MCAO
territory, frozen in liquid nitrogen, and kept at −80◦C for
subsequent RNA analysis. Frozen tissue samples (ipsi- and
contralateral) were weighed and homogenised in a 1ml glass
Dounce homogeniser, and RNA was isolated as described
above using the Stratagene Absolutely RNA mini prep kit
(Stratagene). Sham-operated animals were treated as above
except that no occlusion of the MCA was performed.
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